ReviewGynecologic oncology2010
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
Review in Gynecologic oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.Gynecologic oncology · 2012Pooled it
- Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.Breast cancer research and treatment · 2017Trial
- Article
- Immunostimulatory biomaterials to boost tumor immunogenicity.Biomaterials science · 2020Review
- The era of bioengineering: how will this affect the next generation of cancer immunotherapy?Journal of translational medicine · 2017Review
- Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.Pharmaceutical research · 2016Article
- Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model.Journal of immunology research · 2016Article
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.British journal of cancer · 2015Article
- Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8Oncoimmunology · 2015Article
- Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.Frontiers in immunology · 2013Review
- Emerging therapeutic biomarkers in endometrial cancer.BioMed research international · 2013Review
- Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.Translational oncology · 2012Article
- Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.Journal of translational medicine · 2011Article
- Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?Expert opinion on biological therapy · 2011Review
- Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.Facts, views & vision in ObGyn · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
In the past decade we have witnessed important advances in the treatment of gynecological cancers and have recognized their potential immunogenicity. This has opened the door to explore immune therapy not only in HPV-induced cancers but also in ovarian and endometrial cancers. Here we will review the off-target immune effects of select chemotherapy drugs commonly used to treat gynecologic cancers and novel tools that can stimulate both the adaptive and innate immune mechanisms such as novel pleiotropic cytokines, Toll-like receptors, and powerful antibodies that can target inhibitory checkpoints, thereby activating effector cellular immune mechanisms and neutralizing suppressor cells. We will also review how existing drugs can be used for combinatorial tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.